Navigation Links
Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
Date:8/26/2008

INVESTMENT BANKING FIRM HAS STRONG BACKGROUND IN BIOTECHNOLOGY

SHANGHAI, China, Aug. 26 /PRNewswire-FirstCall/ -- Sinobiomed, Inc. ("Sinobiomed", or "the Company") (OTC Bulletin Board: SOBM) is pleased to announce that it has retained CB Capital Partners, Inc. as its financial advisor to evaluate strategic alternatives to maximize shareholder value.

"While we are extremely pleased with the results obtained from the work undertaken to date on our three marketed and seven pipeline drugs, four of which are moving towards commercial release, we feel this success is not yet represented in shareholder value," said Banjun Yang, Company President and CEO. "We have invested heavily in the respective successful development of our products; now we need assistance in developing our Company's share valuation."

These product developments include:

-- The patented recombinant malaria vaccine candidate (PfCP2.9), for which Sinobiomed is now in discussions to initiate Phase IIb clinical trials

-- The Phase IIb clinical trials of the Company's patented anti-bleeding agent, recombinant Batroxobin (rBAT). Should the product proceed to Phase III clinical trials, it is expected that international governments and organizations would show significant interest. The Company has already received indications of interest from global pharmaceutical companies for joint development, marketing and production.

-- Recent applications for a Chinese and an international patent for recombinant human kallikrein-1 (rhK1), and for a Chinese patent for an innovative recombinant multivalent tuberculosis vaccine.

-- Continuing penetration of Chinese market of Sinobiomed's commercialized products, which treat a wide range of diseases including hepatitis B and hepatitis C. China is home to nearly one third of the world's hepatitis carriers.

"Collectively, these developments have substantially increased the value of Sinobiomed, which has seen a dra
'/>"/>

SOURCE Sinobiomed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Yongye Biotechnology International Retains CCG Investor Relations
2. Shengtai Pharmaceutical Retains Grayling Global As Investor Relations Counsel
3. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
4. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
5. CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing
6. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
7. SPO Medical Retains American Capital Ventures for Investor Relations Services
8. Interleukin Genetics Retains Top Life Science Communications Firms
9. Dragon retains leading investor relations firm
10. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
11. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... YORK , May 22, 2013   ... the development of disease modifying therapeutics for Alzheimer,s ... the completion of its Series B financing, which ... and warrants that would represent approximately $2.8M in ... and new investors supported the raise. ...
(Date:5/22/2013)... 22, 2013  Superior Controls, Inc. has been ... Business NH Magazine.  For the past 22 years, ... distinguish themselves with extraordinary business and civic excellence. ... this honor," said Rick Pierro ... recognition, this award is a reflection of Superior ...
(Date:5/22/2013)... Switzerland (PRWEB) May 22, 2013 ... for industrial biotechnology, drug discovery, and life science ... Genedata Selector ™ as its bioinformatics platform ... production-relevant organisms. Genedata will provide AB Enzymes, one ... with a hosted solution of Genedata Selector accompanied ...
(Date:5/22/2013)... Ontario (PRWEB) May 22, 2013 ... advanced sound therapy for tinnitus treatment. AudioNotch is ... Hearing . With clinic locations in both British ... provider of audiology and hearing services. AudioNotch's tinnitus ... locations. , Upon entering a Destination Hearing clinic, ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2
... of Investment Success -, GAITHERSBURG, Md., Jan. ... of AstraZeneca plc (LSE: AZN.L, NYSE:,AZN), today announced ... will broaden its focus to include areas of ... areas of,cardiovascular and metabolic disease, pain and central ...
... 7 Boston Scientific,Corporation (NYSE: BSX ) today ... Surgery and Vascular Surgery businesses to the Getinge Group ... the definitive agreement,announced on November 5, 2007., The ... in connection with the transaction. These charges will be ...
... MONICA, Calif., Jan. 7 Aida,Pharmaceuticals, Inc. (OTC ... an award from the Science and Technology Department ... China and known throughout,the country for its focus ... because of its "clinical research and,commercialization of Rh-Apo2L" ...
Cached Biology Technology:MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 3Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses 2Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses 3Aida Receives Chinese Government Innovation Award 2
(Date:5/22/2013)... in a major new effort to educate the public ... people with clean water that looms ahead in the ... in the current edition of Chemical & Engineering ... Society (ACS), the world,s largest scientific society. , Bassam ... L. Schnoor, Ph.D., explain that shortages of reliable supplies ...
(Date:5/22/2013)... bacteria is responsible for legionellosis, an infectious disease that ... this pathogen has developed a complex method enabling it ... thus avoiding these acting against the infectious bacteria. , ... bioGUNE, in which teams from the National Institute of ... Centre in Barcelona (BSC) have also participated, has described ...
(Date:5/21/2013)... known for a long time that some creatures evolve ... particularly for plants. But it may be that height ... University and the U. S. National Evolutionary Synthesis Center. ... May in the journal Nature Communications , Lanfear ... , Drawing from a database of global patterns in ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Small but speedy: Short plants live in the evolutionary fast lane 2
... Max Delbrck Center for Molecular Medicine (MDC) Berlin is to ... Prize. The announcement was made by the German Research Foundation ... time the prize will go to the MDC. In 2002 ... will be awarded to a total of eleven scientists: two ...
... mouse model to investigate allergy to fenugreek has been developed ... study cross-reactivity to peanut, soy and lupin, major food allergens ... of the legume family and is used as an ingredient ... be severe yet its presence is rarely declared in ingredient ...
... that are twisted are ubiquitous in nature, and have important ... have unique and technologically useful optical properties; the medicinal properties ... within us think of the double helix twisted ... is called chirality and researchers at Case Western Reserve University ...
Cached Biology News:Nikolaus Rajewsky of the MDC to receive the Leibniz Prize 2New food allergy model for fenugreek developed 2Twisting molecules by brute force: A top-down approach 2Twisting molecules by brute force: A top-down approach 3
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
interferon-related developmental regulator 2...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Human/Mouse/Rat p38 alpha Affinity Purified PAb...
Biology Products: